Generics - Generics, Gilead Sciences

Filter

Current filters:

GenericsGilead Sciences

Popular Filters

Medicines Patent Pool signs record seven sublicenses to speed HIV generics to developing countries

Medicines Patent Pool signs record seven sublicenses to speed HIV generics to developing countries

17-07-2014

Ahead of the International AIDS Conference in Melbourne, Australia, the Medicines Patent Pool has announced…

Anti-viralsatazanavirBristol-Myers SquibbdolutegravirGenericsGilead SciencesMedicines Patent PoolRoche

Drug pricing power led by hepatitis C, diabetes and cancer

Drug pricing power led by hepatitis C, diabetes and cancer

13-06-2014

Hepatitis C, diabetes and cancer are sustaining high pricing power through innovation according to Morningstar's…

AbbVieAntibiotics and Infectious diseasesBiogen IdecCopaxoneDiabetesGenericsGilead SciencesMerck & CoOncologyPharmaceuticalPricingTecfideraTeva Pharmaceutical IndustriesUSA

Lupin no longer trying to market generics of Truvada and Viread

Lupin no longer trying to market generics of Truvada and Viread

08-06-2014

Indian drugmaker Lupin seems to have abandoned plans to bring to market generic versions of Gilead Sciences’…

Anti-viralsGenericsGilead SciencesLegalLupinPatentsTruvadaUSAViread

India/USA trade dispute could impact AIDS treatment programs

10-03-2014

The trade dispute over intellectual property rights between the USA and India is set to derail the distribution…

Anti-viralsCiplaGenericsGilead SciencesGlaxoSmithKlineIndiaPatentsPricingUSA

Gilead and Teva settle Viread patent litigation

20-02-2013

US biotech firm Gilead Sciences (Nasdaq: GILD), a global leader in the HIV/AIDS drug market, has reached…

Anti-viralsBiotechnologyGenericsGilead SciencesNorth AmericaPatentsTeva Pharmaceutical IndustriesViread

Study on generic HIV drugs prompts AHF to demand Gilead cuts ARV prices

16-01-2013

A new study published in the Annals of Internal Medicine that provides a snapshot of a simplified cost/benefit…

Anti-viralsAtriplaGenericsGilead SciencesNorth AmericaPharmaceuticalPricingStribild

News briefs: Genmab/GSK, Gilead and Mylan

24-05-2012

Denmark's Genmab (OMX: GEN) yesterday received a milestone payment of 20 million Danish kroner ($3.4…

Anti-viralsBiotechnologycobicistatFinancialGenericsGenmabGilead SciencesGlaxoSmithKlineMylan LaboratoriesOncologyRegulationViramune

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top